Therefore, both Ortoma and its possible future strategic market commercialization collaboration partners (including the European Company previously mentioned) will continue non-exclusive dialogues for the immediate future. This arrangement will allow on-going dialogues between the parties while also providing for Ortoma’s M&A Advisor to further assess commercialization and M&A scenarios for both regional and global possibilities for Ortoma.

Ortoma Treatment Solution™ - careful planning and precise surgery.

For more information, please contact:

Ortoma CEO Linus Byström, or chairman of the board Gunnar Németh

Email: info@ortoma.com

This information is such information as Ortoma AB (publ) is obliged to disclose in accordance with the EU Market Abuse Regulation. The information was provided through contact with the above contact person for publication on 1 July 2019.

About Ortoma AB (publ)

Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company"s surgical system, Ortoma Treatment Solution™ (OTS) is to enable the surgeon to accurately measure and plan 3D surgery for the placement of a joint implant and during the surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries - and thus better long-term survival rates for the implant. Another aim is to create a system that can be integrated easily into the processes and routines that are currently used in surgeries, thereby increasing efficiency. Ortoma has approximately 1,600 shareholders and the company"s B shares are noted on Spotligh Stockmarket. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden last year around 42,000 surgical procedures were performed involving hip, knee or spinal surgery.